EUVIMEDEUVIMED entdecken
Open Access

Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention

Cameron D Thomas, Jean G Malave, Claudio Laudani, Luis Ortega-Paz, Fabiana Rollini, Larisa H Cavallari, Dominick J Angiolillo, Francesco Franchi

EuroIntervention · 2026

DOI: 10.4244/eij-d-26-00473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EuroIntervention, 2026. Verfasst von Cameron D Thomas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Flo…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dual antiplatelet therapy remains the standard treatment following percutaneous coronary intervention (PCI). While prasugrel and ticagrelor offer consistent antiplatelet effects, they increase bleeding risk compared with clopidogrel, which requires CYP2C19 bioactivation. AIMS: This study aimed to evaluate the impact of rapid CYP2C19 genotyping at the time of PCI on P2Y12 inhibitor selection and clinical outcomes in real-world patients. METHODS: A total of 974 patients who underwent PCI and rapid CYP2C19 genotyping and received P2Y12 inhibitor treatment were included. P2Y12 inhibitor selection, P2Y12 inhibitor switching, major atherothrombotic events (MAE; a composite of all-cause death, myocardial infarction, ischaemic stroke, stent thrombosis, or unstable angina requiring revascularisation), and bleeding events were assessed throughout the first year post-PCI. Time-varying Cox regression analysis was performed to assess event risk in patients treated with clopidogrel (reference) versus prasugrel/ticagrelor after stratifying by loss-of-function (LOF) status and adjusting for stratum-specific confounders. RESULTS: Clopidogrel was prescribed more frequently at discharge among CYP2C19 non-LOF versus LOF carriers (43% [296/691] vs 31% [87/283]; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Percutaneous Coronary InterventionPurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsHumansFemaleMaleAgedClopidogrelMiddle AgedPrasugrel HydrochlorideGenotypeTicagrelorTreatment OutcomeHemorrhage

Substanzen

Cytochrome P-450 CYP2C19Purinergic P2Y Receptor AntagonistsClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochlorideCYP2C19 protein, humanTicagrelor

Autor:innen und Institutionen

  • Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, USA.
  • Department of Clinical & Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA, USA.
  • Division of Cardiology, Department of Medicine, College of Medicine - Jacksonville, University of Florida, Jacksonville, FL, USA.
  • Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.

Förderung

  • NHGRI NIH HHS

Zitieren

APA

Thomas, C. D., Malave, J. G., Laudani, C., Ortega-Paz, L., Rollini, F., Cavallari, L. H., Angiolillo, D. J., & Franchi, F. (2026). Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention. EuroIntervention. https://doi.org/10.4244/eij-d-26-00473

Vancouver

Thomas CD, Malave JG, Laudani C, Ortega-Paz L, Rollini F, Cavallari LH, et al. Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention. EuroIntervention. 2026. doi:10.4244/eij-d-26-00473

BibTeX
@article{Thomas2026,
  author = {Thomas, Cameron D and Malave, Jean G and Laudani, Claudio and Ortega-Paz, Luis and Rollini, Fabiana and Cavallari, Larisa H and Angiolillo, Dominick J and Franchi, Francesco},
  title = {Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention},
  journal = {EuroIntervention},
  year = {2026},
  doi = {10.4244/eij-d-26-00473}
}
Kostenlos starten →